105
Participants
Start Date
May 31, 2006
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2010
Mapatumumab
10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Mapatumumab
20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Bortezomib
1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Department of Haematology, Royal North Shore Hospital, St Leonards
Peter MacCallum Cancer Centre, East Melbourne
Clinical Haematology & BMT, Alfred Hospital, Melbourne
Institute of Medical & Veterinary Science, Adelaide
Roswell Park Cancer Institute, Buffalo
Center for Cancer and Blood Disorders, Bethesda
Cancer and Blood Disorders Center, Lecanto
University of Chicago, Chicago
Capitol Comprehensive Cancer Care Clinic, Jefferson City
Nebraska Methodist Cancer Center, Omaha
Mayo Clinic Arizona, Scottsdale
Scripps Clinic Medical Group, Inc., La Jolla
Bangalore Institute of Oncology, Bangalore
Tom Baker Cancer Center, Calgary
Cross Cancer Institute, Edmonton
Ottawa Health Research Institute - General Campus, Ottawa
Notre Dame Centre Hospitalier de l'Universite de Montreal, Montreal
Bharath Hospital & Institute of Oncology, Mysore
All India Institute of Medical Sciences, New Delhi
Rajiv Gandhi Cancer Institute & Research Center, New Delhi
Lead Sponsor
Human Genome Sciences Inc.
INDUSTRY